Status: Recruiting
Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation
This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy (PBMT) using a novel LED device. The name of the study device involved in this study is: \- THOR LX2.3 with LED Lollipop
Participants needed: 20
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Dana-Farber Cancer InstituteUpdated: Dec 15, 2025Locations: 1
Eligibility criteria
Planned to undergo myeloablative allogeneic HCT using FluBu4 conditioning and Ta... [+2]
Participants who have had treatment with intraoral PBMT within four weeks of adm... [+3]